PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
May 03, 2024 11:00 ET
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
April 23, 2024 08:15 ET
|
Silo Pharma, Inc.
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”),...
PharmAla Closes Private Placement and Concurrent Debt Settlement
April 19, 2024 08:35 ET
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 20, 2024 08:30 ET
|
Silo Pharma, Inc.
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma,...
Global Post-traumatic Stress Disorder (PTSD) Drug Pipeline Landscape Report 2024 Featuring Tonix Pharmaceuticals, Pop Test Oncology, H. Lundbeck, Bionomics, and Alto Neuroscience
February 29, 2024 11:06 ET
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
February 09, 2024 19:30 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
electroCore Expands Intellectual Property Portfolio
January 09, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
PTSD: The Brain Basis of Susceptibility - A Free Webinar from the Brain & Behavior Research Foundation
January 03, 2024 09:04 ET
|
Brain & Behavior Research Foundation
New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at...
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
January 02, 2024 08:00 ET
|
Healis Therapeutics
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
December 13, 2023 18:16 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS